Articles tagged with Myeloid Leukemia
A phase 2 study found that 42% of older patients with acute myeloid leukemia (AML) can remain cancer-free after reduced-intensity stem cell transplantation, challenging traditional age-based exclusion criteria. This approach may offer improved outcomes for AML patients over 60 with otherwise well-tolerated treatments.
Acute myeloid leukemia cells are addicted to the presence of JMJD1C, a protein that plays a key role in cancer-promoting effects. The team identified JMJD1C as a potential therapeutic target for multiple types of leukemia.
Researchers at VCU Massey Cancer Center found that depleting CHD4 protein makes AML cells more susceptible to chemotherapy agents, reducing DNA damage repair and tumor-forming properties.
A protein-coding gene called hnRNP K has been identified as a potential target for treating acute myeloid leukemia. The study found that expression of hnRNP K is significantly reduced in AML patients who carry a specific genetic deletion, suggesting it acts as a tumor suppressor.
A new study reveals that social factors such as insurance status, marital status, and county-level income significantly affect the chances of survival in young patients with acute myelogenous leukemia (AML). The findings highlight the need to address these non-biological patient characteristics to improve health outcomes.
Researchers at Penn State College of Medicine have discovered a potential target for treating acute myeloid leukemia (AML) relapse after stem cell transplant. They found that exhausted T cells, specifically PD-1hiTIM-3+ cells, play a key role in AML relapse.
Researchers have discovered a new molecule that can target the STAT3 protein, which interferes with chemotherapy in patients with acute myeloid leukemia. The molecule, MM-206, locates and attacks a previously unknown binding site on STAT3, disrupting its disease-promoting effects.
Research found that persistent genetic mutations in at least 5% of bone marrow cells are associated with increased risk of relapse and reduced overall survival for leukemia patients. The study provides a foundation for genomic methods to risk stratify patients with acute myeloid leukemia.
Researchers found that patients with acute myeloid leukemia (AML) who retained genetic mutations after chemotherapy were more likely to relapse and die. This approach to genetic profiling could help predict prognosis and determine treatment response, potentially improving outcomes for AML patients.
Researchers tested the novel next-generation small molecule drug SGI-110 in MDS and AML patients, revealing it is well-tolerated and biologically active. The study found potent dose-related DNA demethylation associated with clinical response, showing promise for treating leukemia patients.
Researchers at University of California, San Diego School of Medicine discovered a protein's critical role in developing and progressing acute myeloid leukemia. Blocking this molecule leads to a profound inhibition of leukemia growth, offering a novel target for better treating AML.
A new drug derived from avocado molecules has shown promising results in treating acute myeloid leukemia (AML) by targeting leukemia stem cells. The drug, named avocatin B, has been confirmed to target stem cells selectively, leaving healthy cells unharmed.
Researchers found that ITIM-receptor signaling supports AML development and suggests blocking this pathway may be an effective strategy for treatment. The study provides new insights into the immune system's role in cancer and may lead to novel therapies for acute myeloid leukemia.
A new molecule designed to specifically target a cancer-causing transcription factor has shown potential to extend survival in some leukemia patients. The small molecule, AI-10-49, inhibits the progression of acute myeloid leukemia (AML) by sequestering an oncogenic mutant, leaving normal transcription factor activity intact.
Researchers at National University of Singapore have found new interactions between STAT3 and PRL-3, two molecules involved in acute myeloid leukaemia, which may offer a new therapeutic target. The study suggests that disrupting the STAT3-PRL-3 regulatory loop could lead to an attractive anti-leukaemia therapy.
Research suggests that P53 gene mutations accumulate in blood stem cells as people age, increasing the risk of therapy-related AML. The study found nearly 50% of healthy individuals over 68 had P53 mutations, and these mutations can contribute to chemotherapy resistance.
A phase two study demonstrated that a combination of azacitidine and lenalidomide is an effective frontline treatment regimen for patients with higher-risk forms of myelodysplastic syndrome and acute myeloid leukemia. The therapy was well tolerated in the study of 88 patients.
A phase 2 multicenter trial of ABT-199 found encouraging results in patients with relapsed or resistant acute myelogenous leukemia, with five patients achieving eradication and several more experiencing stable disease. The oral inhibitor targets the BCL-2 protein, which is linked to resistance and poor prognosis in AML patients.
Researchers have discovered novel combinations of targeted therapies and chemotherapy regimens that improve survival outcomes for patients with historically poor-prognosis leukemia. These findings, presented at the American Society of Hematology Annual Meeting, offer new hope for elderly and aggressive genetic mutation patients.
A phase three study has demonstrated increased survival rates among AML patients who relapse, with combination therapy employing cytarabine and vosaroxin showing significant benefits. Patients over 60 years old experienced the greatest overall survival benefit from the treatment.
The investigational drug AG-120 has demonstrated 'extremely promising' early phase 1 clinical trial results for patients with acute myeloid leukemia (AML) harboring IDH1 mutations. This finding builds on previous phase 1 results of a related drug, AG-221, and offers hope for the treatment of this high-risk population.
A novel study by Singapore researchers found that an increase in the Leo1 gene affects genes directly implicated in acute myelogenous leukaemia (AML), increasing cancer incidence. Inhibition of Leo1 and downstream signalling pathways offer a targeted treatment approach.
A team of researchers has identified 5-lipoxygenase as a target for therapeutic management of stem cell-like cells in acute myeloid leukemia. Inhibiting this enzyme selectively attacks and eliminates leukemic stem cells in both cell culture models and mouse models, suggesting a promising approach for treating the disease.
Moffitt Cancer Center's phase 3 study shows CPX-351 leads to higher remission rates compared to standard options in AML, offering a new game-changer for treatment. The innovative drug combination works by maintaining an optimal ratio of cytarabine and daunorubicin inside lipid vesicles.
Researchers at Ohio State University found that microRNA-3151 promotes AML-cell growth and survival by blocking tumor-suppressor gene TP53. High expression of miR-3151 is associated with a bad prognosis, while inhibition with the drug bortezomib offers a possible therapy.
Dr. John F. DiPersio is recognized for his work on experimental sequencing of cancer genomes, personalized medicine, and stem cell transplantation. He will present a lecture on graft-versus-host disease vs. graft-versus-leukemia.
Researchers at UT Health Science Center identified a key role of the WTAP protein in AML development and found that suppressing it with Hsp90 inhibition greatly suppressed proliferation and induced differentiation. This discovery opens up new avenues for effective therapies for children and adults with newly diagnosed AML.
Researchers at Dana-Farber Cancer Institute found that the normal enzyme SYK pairs with mutated FLT3 to promote AML progression and resistance to treatment. Combination therapy involving SYK and FLT3 inhibitors showed significant promise in treating AML.
Researchers found that methylation patterns in acute myeloid leukemia patient samples were prognostic for overall survival. A novel biomarker for lysosomal storage disorders was also identified by correlating relative acidic compartment volumes with clinical severity.
A study by Einstein researchers identified a chemical 'signature' in blood-forming stem cells that predicts which AML patients will respond to chemotherapy. The findings, based on nearly 700 patient data, could help physicians identify patients who would benefit from standard treatment and spare them debilitating side effects.
A genetically engineered mouse model has demonstrated the potent oncogenic role of mutant IDH2 protein in acute myeloid leukemia. The study provides a new tool for evaluating the pharmacological efficacy of potential mutant IDH2 inhibitors and confirms the relevance of this protein as a therapeutic target.
Researchers at Columbia University Medical Center found a single mutation in osteoblasts can cause AML in mice and nearly 40% of patients with the disease. The mutation leads to cancer in adjacent bone-marrow stem cells through signaling pathways.
The EORTC-GIMEMA AML-12 Trial found that high-dose cytarabine improved outcomes for adult patients with acute myeloid leukemia, especially those younger than 46 years. High-dose treatment resulted in higher remission and survival rates compared to standard-dose treatment.
Researchers used genetic information from fruit fly studies to develop a therapeutic strategy that stops an aggressive form of leukemia in laboratory models. They found that targeting microRNAs can significantly improve current therapies for acute myelogenous leukemia, a deadly disease with poor prognosis.
Researchers discovered Sox4 as a potential therapeutic target and histone deacetylase inhibitors as candidates in the treatment of AML. The studies also found that targeting Sox4 effectively perturbs major leukemogenic phenotypes and reactivates expression of genes responsible for blocking growth of healthy blood cells.
A study led by St. Jude Children's Research Hospital found that combining gemtuzumab ozogamicin with conventional chemotherapy improves the outcome of bone marrow transplantation for some children with high-risk acute myeloid leukemia. The treatment helped eliminate minimal residual disease, leading to better patient survival rates.
The EORTC/GIMEMA 06012 trial found sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy has no benefit for older patients with acute myeloid leukemia. GO is too toxic for patients over 70 years old, whereas younger patients may potentially benefit from such treatment.
Researchers from Cincinnati Children's Hospital Medical Center found that inhibiting RUNX1 protein could be a promising therapeutic strategy for acute myeloid leukemia. The study suggests that blocking this protein may stop the development of leukemia cells, offering potential new treatment options.
Researchers found that cancer cells are putting healthy stem cells to sleep, preventing them from forming new blood cells. This discovery offers a potential new approach to treating Acute Myeloid Leukaemia (AML), which affects around 2,500 people in the UK each year.
A new liposomal formulation of anthracycline-based chemotherapy has shown promising results in treating pediatric leukemia patients, with high survival rates and minimal heart toxicity. The treatment regimen was found to be effective at higher-than-standard doses without causing added cardiotoxicity.
Two studies from The Cancer Genome Atlas program reveal genomic landscapes of AML and endometrial cancer, providing new insights into molecular underpinnings. The studies identify four novel tumor subtypes in endometrial cancer and show genomic similarities with other types of cancers.
Researchers have identified nearly all major genetic mutations that drive acute myeloid leukemia (AML), a fast-growing blood cancer. The study paves the way for developing personalized treatment plans based on a patient's genetic profile.
Researchers at Cedars-Sinai Medical Center discovered that the renin angiotensin system plays a fundamental role in hypertension. They found that mice without ACE in their kidneys were resistant to high blood pressure, indicating that targeting angiotensin production may be an effective approach to treat hypertension. In contrast, stud...
Researchers at RIKEN have identified a compound that could be used to prevent relapse in acute myeloid leukemia patients, particularly those with the FLT3-ITD mutation. The compound targets human primary AML stem cells and reduces AML cell counts in mouse models.
Kantarjian's contributions to leukemia treatment have improved survival rates from 50% to 90% with BCR-ABL inhibitors. His work also led to standardization of combination therapies and FDA approval for ruxolitinib, a treatment for myelofibrosis.
Researchers at the University of Minnesota have identified a genetic variation in CD33 that significantly affects the clinical outcome of AML patients who received gemtuzumab ozogamicin chemotherapy. This discovery may help predict which patients are most likely to benefit from the treatment and improve therapeutic efficacy.
A Phase II clinical trial found that over a third of high-risk leukemia patients responded to the experimental new drug quizartinib, experiencing complete remission and potentially life-saving bone marrow transplants. Many participants who did well with the drug had failed to respond to prior therapies.
A new study finds that a reduced intensity conditioning regimen before marrow transplant significantly boosts disease-free survival rates among older AML patients. With a rate of 39%, this approach outperforms traditional methods in preventing relapse and improving patient outcomes.
In pre-clinical experiments, Angiocidin reduced acute myeloid leukemia (AML) cells by almost two-thirds, demonstrating its potential as a safer treatment alternative to standard-of-care chemotherapy agents like Ara-C. The protein also stimulated maturation in affected white cells, causing them to behave like normal cells.
Researchers present promising results from a Phase II study on quizartinib, a targeted therapy that may turn treatment-resistant leukemia into manageable conditions. The study shows great potential in turning fatal disease subtypes into chronic conditions with regular treatment.
Researchers found that a specific genetic marker, WT1 SNP rs16754, is correlated with improved outcomes and reduced treatment-related mortality in pediatric patients with AML. The study suggests personalized cancer treatment may improve survival and reduce toxicity by considering individual genetic makeup.
Researchers have discovered that lithium restores cognitive function in Down syndrome mice, while stem cell-derived dopaminergic neurons improve motor defects in Parkinson's disease monkeys. Additionally, inhibiting a key protein in Alzheimer's disease may reduce plaque formation and improve memory tasks. Moreover, tempering inflammati...
A study published in the Journal of Clinical Investigation found that a transcriptional regulator called C/EBPG was highly expressed in AML samples with an epigenetically silenced C/EBPA gene. By blocking this epigenetic modification, researchers were able to reduce C/EBPG and restore normal myeloid blood cells.
A Wake Forest Baptist researcher discovered that high levels of the MN1 gene accelerate Acute Myeloid Leukemia (AML) and reduce chemotherapy's effectiveness. The study found that the p53 protein is not functioning properly in cells expressing high levels of MN1, leading to a poorer prognosis.
Researchers developed a novel method to determine how ready acute myeloid leukemia (AML) cells are to die, helping cancer specialists choose treatments more effectively. The tool measures the 'primed to die' status of AML cells by apoptosis, allowing for better prediction of patient outcomes and personalized treatment decisions.
A new diagnostic test has been identified as the most effective method for measuring treatment response in young patients with acute myeloid leukemia, which could lead to a higher cure rate. The test uses flow cytometry to identify minimal residual disease in patient bone marrow, allowing for more intensive therapy to be guided.
Dr. Ley's work on whole genome sequencing in AML has provided unprecedented insights into the disease, highlighting the importance of unbiased methods for discovering cancer-initiated mutations. His research also revealed that most AML mutations are benign background events, with only a handful contributing to pathogenesis.
Scientists at Albert Einstein College of Medicine have discovered a gene called HLX that is over-expressed in leukemia stem cells, leading to the development of abnormal white blood cells. Targeting elevated HLX expression may be a promising novel strategy for treating acute myeloid leukemia.
Researchers found a new pathway activated by FLT3 mutation in acute myeloid leukemia, leading to the activation of CDK1 and promoting cell differentiation. Clinical trials with CDK1 inhibitors are underway, suggesting therapies targeting this pathway may be effective for patients resistant to existing treatments.
Researchers have discovered a new target for treating acute myeloid leukemia by targeting cyclin-dependent kinase 1 (CDK1), which promotes differentiation of cancer cells. Additionally, inflammation has been found to play a significant role in age-related retinal degeneration.